KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $68.49 $68.49 Friday, 27th Jan 2023 GBT stock ended at $68.49. During the day the stock fluctuated 0% from a day low at $68.49 to a day high of $68.49.
90 days $68.49 $68.49
52 weeks $21.65 $73.02

Historical GLOBAL BLOOD THERAPEUTICS prices

Date Open High Low Close Volume
Oct 10, 2022 $68.49 $68.49 $68.49 $68.49 0
Oct 07, 2022 $68.49 $68.49 $68.49 $68.49 0
Oct 06, 2022 $68.49 $68.49 $68.49 $68.49 0
Oct 05, 2022 $68.49 $68.49 $68.49 $68.49 0
Oct 04, 2022 $68.48 $68.49 $68.47 $68.49 3 279 961
Oct 03, 2022 $68.46 $68.48 $68.45 $68.48 3 616 412
Sep 30, 2022 $68.10 $68.28 $68.01 $68.10 2 680 930
Sep 29, 2022 $68.11 $68.19 $67.79 $68.07 2 083 094
Sep 28, 2022 $68.14 $68.19 $67.95 $68.11 2 233 883
Sep 27, 2022 $67.90 $68.19 $67.85 $68.18 1 732 817
Sep 26, 2022 $67.92 $68.13 $67.74 $67.75 1 749 048
Sep 23, 2022 $67.91 $68.04 $67.83 $67.99 1 469 191
Sep 22, 2022 $67.78 $68.09 $67.67 $67.97 1 736 536
Sep 21, 2022 $67.92 $68.20 $67.65 $67.69 2 543 974
Sep 20, 2022 $67.87 $68.15 $67.76 $67.89 3 634 784
Sep 19, 2022 $67.69 $68.03 $67.61 $68.03 2 222 420
Sep 16, 2022 $67.71 $67.78 $67.54 $67.62 5 714 482
Sep 15, 2022 $67.85 $67.89 $67.66 $67.78 2 494 683
Sep 14, 2022 $67.80 $67.95 $67.70 $67.95 3 095 760
Sep 13, 2022 $67.78 $67.98 $67.75 $67.75 2 851 802
Sep 12, 2022 $67.86 $67.93 $67.74 $67.87 3 003 569
Sep 09, 2022 $67.88 $68.03 $67.76 $67.76 3 707 660
Sep 08, 2022 $67.94 $67.99 $67.70 $67.98 3 460 916
Sep 07, 2022 $67.75 $68.05 $67.73 $67.99 2 110 148
Sep 06, 2022 $67.91 $67.96 $67.68 $67.88 4 256 421
Click to get the best stock tips daily for free!

About GLOBAL BLOOD THERAPEUTICS

GLOBAL BLOOD THERAPEUTICS Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, ... GBT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT